Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ESTA NASDAQ:MDXG NASDAQ:SMTI NASDAQ:SSII On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeESTAEstablishment Labs$37.47-0.9%$40.85$26.56▼$50.85$1.09B0.85252,313 shs313,935 shsMDXGMiMedx Group$6.94-2.8%$6.98$5.47▼$10.14$1.03B1.74414,574 shs418,141 shsSMTISanara MedTech$33.96-3.7%$29.59$23.53▼$39.08$302.32M1.1929,128 shs29,571 shsSSIISS Innovations International$5.80-7.9%$6.65$2.48▼$22.42$1.12BN/A43,022 shs71,574 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceESTAEstablishment Labs0.00%-4.00%-1.26%+0.08%-8.59%MDXGMiMedx Group0.00%-2.80%-2.94%+14.90%+12.12%SMTISanara MedTech0.00%+1.16%+11.71%+17.88%+1.34%SSIISS Innovations International0.00%-17.14%-14.07%+63.84%+579,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeESTAEstablishment Labs$37.47-0.9%$40.85$26.56▼$50.85$1.09B0.85252,313 shs313,935 shsMDXGMiMedx Group$6.94-2.8%$6.98$5.47▼$10.14$1.03B1.74414,574 shs418,141 shsSMTISanara MedTech$33.96-3.7%$29.59$23.53▼$39.08$302.32M1.1929,128 shs29,571 shsSSIISS Innovations International$5.80-7.9%$6.65$2.48▼$22.42$1.12BN/A43,022 shs71,574 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceESTAEstablishment Labs0.00%-4.00%-1.26%+0.08%-8.59%MDXGMiMedx Group0.00%-2.80%-2.94%+14.90%+12.12%SMTISanara MedTech0.00%+1.16%+11.71%+17.88%+1.34%SSIISS Innovations International0.00%-17.14%-14.07%+63.84%+579,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceESTAEstablishment Labs 2.83Moderate Buy$56.5050.79% UpsideMDXGMiMedx Group 3.00Buy$12.0072.91% UpsideSMTISanara MedTech 3.00Buy$50.0047.23% UpsideSSIISS Innovations International 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest SMTI, SSII, ESTA, and MDXG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/20/2025ESTAEstablishment LabsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$60.008/18/2025SMTISanara MedTechHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$53.00 ➝ $54.008/18/2025SMTISanara MedTechHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$53.00 ➝ $54.007/31/2025MDXGMiMedx GroupCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$11.00 ➝ $12.007/16/2025ESTAEstablishment LabsMizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$58.00 ➝ $70.007/15/2025MDXGMiMedx GroupCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$11.007/9/2025ESTAEstablishment LabsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$38.00 ➝ $47.00(Data available from 9/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookESTAEstablishment Labs$166.02M6.54N/AN/A$1.90 per share19.72MDXGMiMedx Group$348.88M2.94$0.33 per share20.95$1.31 per share5.30SMTISanara MedTech$86.67M3.49N/AN/A$4.45 per share7.63SSIISS Innovations International$20.65M54.37N/AN/A$0.08 per share72.50Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateESTAEstablishment Labs-$84.60M-$3.05N/AN/AN/A-49.89%-224.34%-25.53%11/6/2025 (Estimated)MDXGMiMedx Group$42.42M$0.2133.0521.69N/A8.84%23.03%17.09%10/29/2025 (Estimated)SMTISanara MedTech-$9.66M-$1.16N/AN/AN/A-10.22%-26.43%-10.69%11/11/2025 (Estimated)SSIISS Innovations International-$19.15MN/A0.00∞N/A-40.20%-40.41%-20.80%N/ALatest SMTI, SSII, ESTA, and MDXG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025SMTISanara MedTech-$0.33-$0.23+$0.10-$0.23$25.15 million$25.83 million8/7/2025Q2 2025ESTAEstablishment Labs-$0.54-$0.57-$0.03-$0.57$50.80 million$51.30 million7/30/2025Q2 2025MDXGMiMedx Group$0.06$0.10+$0.04$0.06$90.79 million$98.61 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthESTAEstablishment LabsN/AN/AN/AN/AN/AMDXGMiMedx GroupN/AN/AN/AN/AN/ASMTISanara MedTechN/AN/AN/AN/AN/ASSIISS Innovations InternationalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioESTAEstablishment Labs9.712.841.67MDXGMiMedx Group0.084.393.90SMTISanara MedTech1.252.262.03SSIISS Innovations InternationalN/A2.591.66Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipESTAEstablishment Labs72.91%MDXGMiMedx Group79.15%SMTISanara MedTech8.10%SSIISS Innovations InternationalN/AInsider OwnershipCompanyInsider OwnershipESTAEstablishment Labs11.44%MDXGMiMedx Group1.70%SMTISanara MedTech42.60%SSIISS Innovations InternationalN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableESTAEstablishment Labs1,01828.97 million25.66 millionOptionableMDXGMiMedx Group870147.96 million145.44 millionOptionableSMTISanara MedTech608.90 million5.11 millionNot OptionableSSIISS Innovations International4193.59 millionN/AN/ASMTI, SSII, ESTA, and MDXG HeadlinesRecent News About These CompaniesCFO Stepping Down Introduces Uncertainty At SS Innovations International (SSII)September 13 at 6:11 PM | finance.yahoo.comSS Innovations International (NASDAQ:SSII) Stock Price Down 7.4% - Time to Sell?September 12 at 5:29 PM | marketbeat.comSS Innovations International (NASDAQ:SSII) Shares Gap Down - Here's What HappenedSeptember 10, 2025 | marketbeat.comSS Innovations Announces Successful Completion of First Robotic Telesurgery Performed from the Company’s MantraM Mobile Robotic Telesurgery UnitSeptember 9, 2025 | markets.businessinsider.comSS Innovations International, Inc. Achieves Milestone with First Robotic Telesurgery from MantraM Mobile UnitSeptember 9, 2025 | quiverquant.comQSS Innovations Announces Successful Completion of First Robotic Telesurgery Performed from the Company's MantraM Mobile Robotic Telesurgery UnitSeptember 9, 2025 | prismmediawire.comPSS Innovations Announces Successful Completion of First Robotic Telesurgery Performed from the Company's MantraM Mobile Robotic Telesurgery UnitSeptember 9, 2025 | globenewswire.comSS Innovations International (NASDAQ:SSII) Shares Down 6.7% - Should You Sell?September 5, 2025 | marketbeat.comSS Innovations International (NASDAQ:SSII) Stock Price Up 17.1% - Still a Buy?August 24, 2025 | marketbeat.comSS Innovations International (NASDAQ:SSII) Shares Gap Down - Time to Sell?August 20, 2025 | marketbeat.comSS Innovations International (NASDAQ:SSII) Shares Gap Up - Should You Buy?August 16, 2025 | marketbeat.comSS Innovations International Inc. Stock Grades | SSII | Barron'sAugust 15, 2025 | barrons.comSs Innovations (SSII) Q2 Revenue Up 122%August 8, 2025 | aol.comASS Innovations Reports Second Quarter 2025 Financial ResultsAugust 7, 2025 | prismmediawire.comPSS Innovations Reports Second Quarter 2025 Financial ResultsAugust 7, 2025 | globenewswire.comSS Innovations Announces Completion of World’s First Intercontinental Robotic Cardiac TelesurgeryJuly 23, 2025 | finance.yahoo.comSS Innovations Announces Completion of World's First Intercontinental Robotic Cardiac TelesurgeryJuly 22, 2025 | prismmediawire.comPSS Innovations Announces Completion of World's First Intercontinental Robotic Cardiac TelesurgeryJuly 22, 2025 | globenewswire.comSSII - SS Innovations International Inc Ownership | MorningstarJuly 17, 2025 | morningstar.comMSS Innovations Surpasses Milestone of 100 Installations of the SSi Mantra Surgical Robotic SystemJuly 15, 2025 | prismmediawire.comPSS Innovations Announces Completion of World's First Robotic Telesurgery for Weight Loss with the Company's SSi Mantra 3 Surgical Robotic SystemJuly 10, 2025 | prismmediawire.comPNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025NIO Just Got Its Second Upgrade of the Month, and It’s BigBy Sam Quirke | August 28, 2025With Rate Cuts Ahead, Buffett-Backed Builders Look Like a BuyBy Jordan Chussler | September 4, 20253 Stocks Poised to Gain from a September Rate CutBy Chris Markoch | September 4, 2025SMTI, SSII, ESTA, and MDXG Company DescriptionsEstablishment Labs NASDAQ:ESTA$37.47 -0.34 (-0.90%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$37.49 +0.02 (+0.07%) As of 09/12/2025 05:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander. The company sells its products to physicians, hospitals, and clinics through distributors and direct sales force in Europe, the Middle East, Latin America, and Asia. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.MiMedx Group NASDAQ:MDXG$6.94 -0.20 (-2.80%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$6.93 -0.01 (-0.14%) As of 09/12/2025 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications. The company's products have applications in the areas of wound care, burn, surgical sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.Sanara MedTech NASDAQ:SMTI$33.96 -1.32 (-3.74%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$33.98 +0.02 (+0.05%) As of 09/12/2025 05:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. It also provides BIAKOS Antimicrobial Skin and Wound Cleanser, a patented product that contains synergistic ingredients that have been shown to impact mature biofilm microbes; BIAKOS Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing that helps against planktonic microbes, as well as immature and mature biofilms; and BIAKOS Antimicrobial Skin and Wound Irrigation Solution. In addition, it develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement; and VIM Amnion Matrix, a homologous wound covering product. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.SS Innovations International NASDAQ:SSII$5.80 -0.50 (-7.94%) As of 09/12/2025 04:00 PM EasternAVRA Medical Robotics, Inc. develops and manufactures medical surgical devices. The company has a research agreement with the University of Central Florida to develop navigation and control technologies with applications in medical robotics. The company was formerly known as AVRA Surgical Microsystems, Inc. and changed its name to AVRA Medical Robotics, Inc. in November 2015. AVRA Medical Robotics, Inc. was founded in 2015 and is based in Orlando, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Football Season Is Here and DraftKings Stock Is Surging RH Stock Slides After Mixed Earnings and Tariff Concerns Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
